Course "Surviving an FDA Inspection: Understand the Do's and Don'ts and the Ground Rules" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
Overview:
Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. Emphasis is placed on the company's SOP on dealing with inspectors and knowing how to be prepared, proactive...and being able to defend and justify... and what it takes to achieve a favorable outcome. This seminar provides background and understanding of the role played by the Agency, its administrative and enforcement powers. It takes the participant step by step through the entire inspection process and describes various types of inspections.
Who will benefit:
This seminar will provide valuable assistance and guidance to all regulated companies that are preparing for FDA inspections. The employees who will benefit include:
• All levels of Management for all departments
• QA/QC/Compliance/Regulatory Affairs
• Information Technology/Marketing & Sales
• Engineering/Technical Services/Validation
• Consultants
• Operations and Manufacturing
Agenda:
Day 1 Schedule:
Lecture 1: How a firm should prepare for an FDA inspection
Lecture 2: Ways to train employees in view of the inspection
Lecture 3: How to ensure that required documentation is in place
Lecture 4: How to interact with the investigator-DO and DON'T's
Lecture 5: What companies should do when the inspection ends
Lecture 6: How to reply to 483's and warning letters
Lecture 7: Legal implications of non-compliance
Lecture 8: Post inspection actions
Day 2 Schedule:
Lecture 1: Why inspections are conducted and by what statutory authority
Lecture 2: The emphasis on systems-based inspections...and the IOM and other crucial FDA reference documents
Lecture 3: What is subject to FDA purview and what's off-limits
Lecture 4: Understand and apply the do's and don'ts and comprehend that preparation is the key to success
Lecture 5: What are the prohibited "Acts" and the enforcement categories that you need to deal with
Lecture 6: What you need to know and do to prepare for, during and even after the inspection...and why your inspection response team is key
Lecture 7: The Company’s Inspection Plan (SOP) can make or break the inspection depending on how to use it and training your personnel
Lecture 8: How to respond to findings and facilitating the documentation and remediation process...and reaching final closure
Lecture 9: Define clear responsibilities, roles and goals for personnel involved in SOP development
Speaker:
David R. Dills
Regulatory Affairs & Compliance Consultant,
David R. Dills Regulatory Affairs & Compliance Consultant currently provides regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III device, In Vitro Diagnostics, and bio/pharmaceutical manufacturers on the global landscape, and also has an accomplished record with more than 25 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by medical device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA's, warning letters, 483 observations, and customer generated compliance events, and prepares for and conducts QS and regulatory audits.
He has been directly involved with constructing, reviewing, and/or remediating regulatory submissions, including 510(k), PMA, IDE applications, BLA and NDA submissions, preparing Supplements, Amendments, U.S. Agent for clients, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs and study submissions; and provides regulatory submissions and post-market project leadership and guidance covering different therapeutic and medical specialties based on classification.
Mr. Dills has a strong background in the interpretation and applicability of FDA regulations, including 21 CFR 210/211, 21 CFR 820, GMP Quality System implementation and compliance requirements, conducts customized GxP training, leads and directs activities for the registration and approval process and working with Agencies in the Pacific Rim, EU and The Americas, including but not limited to FDA, European Medicines Agency-EMA, MHRH, ANVISA, PMDA, TGA, and Health Canada; and defining and executing regulatory compliance, risk mitigation and remediation strategies in response to inspection findings. Additional activities include Pre-FDA Facility Inspections, Mock Audits/Due diligence and assessing state of readiness for Pre-approval inspection (PAI/PMA), proof of management oversight, facilitate and direct efforts for remediation planning and monitoring, and assessment of the critical sub-systems, records and document controls.
Location Boston, MA Date: December 10th & 11th, 2015 Time: 9 AM to 6 PM
Venue: Courtyard Boston Logan Airport
Address: 225 William F McClellan Hwy, Boston, MA 02128, United States
Price: $1,295.00 (Seminar for One Delegate)
Register now and save $200.
Until November 15, Early Bird Price: $1,295.00
From November 16 to December 08, Regular Price: $1,495.00
Registration Details:
NetZealous LLC - DBA GlobalCompliancePanel
161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
USA Phone: 1-800-447-9407
Fax: 302-288-6884
support@globalcompliancepanel.com
http://www.globalcompliancepanel.com
Registration Link - http://bit.ly/1H5U77T
Overview:
Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. Emphasis is placed on the company's SOP on dealing with inspectors and knowing how to be prepared, proactive...and being able to defend and justify... and what it takes to achieve a favorable outcome. This seminar provides background and understanding of the role played by the Agency, its administrative and enforcement powers. It takes the participant step by step through the entire inspection process and describes various types of inspections.
Who will benefit:
This seminar will provide valuable assistance and guidance to all regulated companies that are preparing for FDA inspections. The employees who will benefit include:
• All levels of Management for all departments
• QA/QC/Compliance/Regulatory Affairs
• Information Technology/Marketing & Sales
• Engineering/Technical Services/Validation
• Consultants
• Operations and Manufacturing
Agenda:
Day 1 Schedule:
Lecture 1: How a firm should prepare for an FDA inspection
Lecture 2: Ways to train employees in view of the inspection
Lecture 3: How to ensure that required documentation is in place
Lecture 4: How to interact with the investigator-DO and DON'T's
Lecture 5: What companies should do when the inspection ends
Lecture 6: How to reply to 483's and warning letters
Lecture 7: Legal implications of non-compliance
Lecture 8: Post inspection actions
Day 2 Schedule:
Lecture 1: Why inspections are conducted and by what statutory authority
Lecture 2: The emphasis on systems-based inspections...and the IOM and other crucial FDA reference documents
Lecture 3: What is subject to FDA purview and what's off-limits
Lecture 4: Understand and apply the do's and don'ts and comprehend that preparation is the key to success
Lecture 5: What are the prohibited "Acts" and the enforcement categories that you need to deal with
Lecture 6: What you need to know and do to prepare for, during and even after the inspection...and why your inspection response team is key
Lecture 7: The Company’s Inspection Plan (SOP) can make or break the inspection depending on how to use it and training your personnel
Lecture 8: How to respond to findings and facilitating the documentation and remediation process...and reaching final closure
Lecture 9: Define clear responsibilities, roles and goals for personnel involved in SOP development
Speaker:
David R. Dills
Regulatory Affairs & Compliance Consultant,
David R. Dills Regulatory Affairs & Compliance Consultant currently provides regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III device, In Vitro Diagnostics, and bio/pharmaceutical manufacturers on the global landscape, and also has an accomplished record with more than 25 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities by medical device manufacturers and consultancies, including a globally recognized CRO and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA's, warning letters, 483 observations, and customer generated compliance events, and prepares for and conducts QS and regulatory audits.
He has been directly involved with constructing, reviewing, and/or remediating regulatory submissions, including 510(k), PMA, IDE applications, BLA and NDA submissions, preparing Supplements, Amendments, U.S. Agent for clients, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs and study submissions; and provides regulatory submissions and post-market project leadership and guidance covering different therapeutic and medical specialties based on classification.
Mr. Dills has a strong background in the interpretation and applicability of FDA regulations, including 21 CFR 210/211, 21 CFR 820, GMP Quality System implementation and compliance requirements, conducts customized GxP training, leads and directs activities for the registration and approval process and working with Agencies in the Pacific Rim, EU and The Americas, including but not limited to FDA, European Medicines Agency-EMA, MHRH, ANVISA, PMDA, TGA, and Health Canada; and defining and executing regulatory compliance, risk mitigation and remediation strategies in response to inspection findings. Additional activities include Pre-FDA Facility Inspections, Mock Audits/Due diligence and assessing state of readiness for Pre-approval inspection (PAI/PMA), proof of management oversight, facilitate and direct efforts for remediation planning and monitoring, and assessment of the critical sub-systems, records and document controls.
Location Boston, MA Date: December 10th & 11th, 2015 Time: 9 AM to 6 PM
Venue: Courtyard Boston Logan Airport
Address: 225 William F McClellan Hwy, Boston, MA 02128, United States
Price: $1,295.00 (Seminar for One Delegate)
Register now and save $200.
Until November 15, Early Bird Price: $1,295.00
From November 16 to December 08, Regular Price: $1,495.00
Registration Details:
NetZealous LLC - DBA GlobalCompliancePanel
161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
USA Phone: 1-800-447-9407
Fax: 302-288-6884
support@globalcompliancepanel.com
http://www.globalcompliancepanel.com
Registration Link - http://bit.ly/1H5U77T
